Tecentriq SC (atezolizumab/hyaluronidase) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq SC (atezolizumab/hyaluronidase) / Roche
2021-004067-28: A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared with Intravenous Atezolizumab Formulation in Participants with Non-Small Cell Lung Cancer STUDIO RANDOMIZZATO, MULTICENTRICO, IN APERTO, DI CROSS-OVER PER LA VALUTAZIONE DELLA PREFERENZA RIPORTATA DAI PARTECIPANTI E DAGLI OPERATORI SANITARI PER ATEZOLIZUMAB SOTTOCUTANEO RISPETTO ALLA FORMULAZIONE ENDOVENOSA DI ATEZOLIZUMAB IN PARTECIPANTI AFFETTI DA CARCINOMA POLMONARE NON A PICCOLE CELLULE

Not yet recruiting
2
140
Europe
Atezolizumab SC, Atezolizumab IV, [RO5541267/F06-02], [RO5541267/F03-01], Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Tecentriq
F. HOFFMANN - LA ROCHE LTD., Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Non-Small Cell Lung Cancer (NSCLC) CARCINOMA POLMONARE NON A PICCOLE CELLULE, Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Smoking is the major risk factor for non-small cell lung cancer. Il carcinoma polmonare non a piccole cellule è una patologia nella quale le cellule del carcinoma maligno si formano nel tessuto del polmone.Il fumo è il maggior fattore di rischio per tale patologia., Diseases [C] - Cancer [C04]
 
 
2021-001415-90: Interventional Platform Study Investigating the Impact of Digital Health Solutions, such as Digital Patient Monitoring (DPM), on Health Outcomes and Health-Care Resource Utilization in Participants Receiving Systemic Treatment in Clinical Practice (Origama) Estudio intervencional tipo plataforma para investigar el impacto de soluciones de salud digital, como Monitorización Digital del Paciente, en los resultados en la salud y la utilización de recursos de atención médica en pacientes que reciben tratamiento sistémico en la práctica clínica (Origama)

Not yet recruiting
2
440
Europe
ATEZOLIZUMAB SC, RO5541267, Solution for injection in vial
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffmann La Roche Ltd., F.Hoffmann-La Roche, Ltd.
Cohort A: ●Metastatic non-small cell lung carcinoma (mNSCLC)●Extensive-stage small-cell lung carcinoma (ES-SCLC)●Advanced or unresectable hepatocellular carcinoma (HCC)Cohort B: Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC) Cohorte A: ●Carcinoma de pulmón no microcítico metastásico (CPNMm)●Carcinoma de pulmón microcítico en estadío extenso (CPM-EE)●Carcinoma hepatocelular (CHC) avanzado o no resecableCohorte B:Cáncer de pulmón no microcítico (CPNM) resecado en estadío IIB-IIIB (estadío inicial, de acuerdo con el sistema de estadificación UICC/AJCC, 8ª edición), Cohort A: People with one of three types of lung or liver cancer Cohort B: People with one type of lung cancer at early stage Cohorte A: personas con uno de los tres tipos de cáncer de pulmón o hígadoCohorte B: personas con un tipo de cáncer de pulmón en estadío inicial, Diseases [C] - Cancer [C04]
 
 
IMscin002, NCT05171777: A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Active, not recruiting
2
176
Europe, Canada, US, RoW
Atezolizumab, Tecentriq
Hoffmann-La Roche
Non-small Cell Lung Cancer
11/23
09/24
NCT05340309: Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Recruiting
2
37
US
Atezolizumab and Recombinant Human Hyaluronidase, Atezolizumab + rHuPH20, Atezolizumab and Hyaluronidase, Atezolizumab with rHuPH20, Atezolizumab-rHuPH20, Atezolizumab/rHuPH20 Co-formulation, Recombinant Human Hyaluronidase Mixed with Atezolizumab, Tecentriq/rHuPH20, Survey Administration
University of Southern California, National Cancer Institute (NCI), Genentech, Inc.
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/26

Download Options